Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q99828

UPID:
CIB1_HUMAN

ALTERNATIVE NAMES:
Calcium- and integrin-binding protein; Calmyrin; DNA-PKcs-interacting protein; Kinase-interacting protein; SNK-interacting protein 2-28

ALTERNATIVE UPACC:
Q99828; B5BU40; H6WJF3; O00693; O00735; Q6IB49; Q96J54; Q99971

BACKGROUND:
The protein Calcium and integrin-binding protein 1, also referred to as Calmyrin, plays a significant role in regulating numerous cellular processes such as thrombosis, angiogenesis, and apoptosis. It is involved in the regulation of cell migration, negatively regulates thrombopoietin-mediated signaling, and plays a role in microtubule dynamics during neuronal development. Additionally, it promotes cardiomyocyte hypertrophy and is involved in keratinocyte-intrinsic immunity to human beta-papillomaviruses.

THERAPEUTIC SIGNIFICANCE:
The association of Calcium and integrin-binding protein 1 with Epidermodysplasia verruciformis 3, a genodermatosis with a predisposition to skin carcinoma, highlights its therapeutic potential. Its involvement in critical pathways such as angiogenesis, tumor growth, and cellular immunity positions it as a promising target for drug discovery efforts aimed at treating a variety of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.